Herantis Pharma logo
Search
  • About Us
    • Company profile
    • Team
    • Board of Directors
    • Nomination Committee
    • Scientific Advisory Board
  • Pipeline
    • Pipeline overview
    • CDNF
    • Next generation xCDNF
    • Lymfactin®
    • Scientific publications
  • Investors
    • Investors
    • Releases
    • Analyst Coverage
    • Financial Calendar
    • General Meetings
    • Financial Information
    • Share Information
    • Major Shareholders
    • Share Monitor
    • Investor Relations
    • Corporate Governance
  • News & Events
    • Herantis in the News
    • Events
    • Releases
    • Public materials
    • Video Presentations
    • Newsletter
  • Patients
    • Overview & Contact Us
    • Parkinson’s Disease
    • Lymphedema
    • Community Resources
  • Contact
  • FIN
Search

Latest releases

  • CDNF releases
  • Earnings Release
  • First north
  • General releases
  • Insider trading
  • Lymfactin releases
  • Newsletter
  • Press Release
  • Clear
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 30.12.2019
    CR, FN, GR
    Herantis Pharma Plc provides update on non-invasive next generation CDNF (xCDNF) development
  • 20.12.2019
    FN, GR
    Herantis Pharma Plc’s financial reporting schedule and annual general meeting in 2020
  • 19.12.2019
    CR, FN
    Herantis Pharma Plc completes patient treatments in main study of Phase 1-2 CDNF trial in Parkinson’s disease
  • 16.12.2019
    FN, LR
    Herantis Pharma Plc completes patient recruitment and treatment in Phase 2 AdeLE trial in breast cancer associated lymphedema
  • 10.12.2019
    FN
    Herantis Pharma Plc has submitted a listing application to Nasdaq Stockholm AB for the listing of the offer shares
  • 09.12.2019
    FN
    Offer shares of Herantis Pharma Plc registered with the Trade Register
  • 02.12.2019
    FN
    Herantis Pharma Plc’s directed share issue is oversubscribed multiple times and completed as planned
  • 11.11.2019
    FN
    Herantis Pharma Plc commences a directed share issue, contemplates secondary listing on Nasdaq First North Growth Market Sweden and expands its management team
  • 26.09.2019
    CR, FN
    Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial
  • 31.05.2019
    FN
    Herantis Pharma Oyj: Manager’s Transactions – Timo Veromaa
  • « Previous page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • ...
  • Page 4
  • Next page »

Quick links

Herantis in the News »
Events »
Releases »
Public materials »
Video Presentations »
Newsletter »
Herantis Pharma logo

HERANTIS PHARMA Plc
Bertel Jungin Aukio 1
FIN-02600 Espoo dsfs

Tel: +358 9 222 1195
Email: info (at) herantis.com
VAT number FI21986657

  • Legal notice
  • Privacy notice
  • Sign up for our bi-monthly newsletter

Copyright © HERANTIS PHARMA Plc. All rights reserved.

Cookies
This website uses cookies and Google Analytics. We use cookies and Google Analytics to adapt the website according to your preferences and to collect information about the use of the website. For more information regarding cookies we request you to review our privacy notice. The following terms and conditions are applied to the use of this website. By continuing to use this website you accept such terms and conditions.
OK
Privacy notice
Legal notice
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT